Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Regorafenib Synergizes With TAS102 Against Multiple Gastrointestinal Cancers

News

July 9, 2024
PRESS RELEASE: On July 2, 2024, a new research paper was published in Oncotarget, entitled, “Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers [...].” continue reading »

Editorial: Genomics Has More to Reveal

News

July 2, 2024
PRESS RELEASE: On June 20, 2024, a new editorial was published in Oncotarget, entitled, “Genomics has more to reveal.” continue reading »

Starving Cancer Cells to Enhance DNA Damage and Immunotherapy Response

News

June 26, 2024
PRESS RELEASE: On June 20, 2024, a new research perspective was published in Oncotarget, entitled, “Starving cancer cells to enhance DNA damage and immunotherapy response.” continue reading »

Leveraging Gold Nanostars for Precision Laser Interstitial Thermal Therapy

News

June 25, 2024
PRESS RELEASE: On June 14, 2024, a new editorial was published in Oncotarget, entitled, “Leveraging gold nanostars for precision laser interstitial thermal therapy.” continue reading »

Impact of Dual Immunotherapies Before Surgery in HR+/HER2-negative Breast Cancer

Oncotarget

June 20, 2024
In this new study, researchers assessed the feasibility of treating HR+/HER2-negative breast cancer patients with the immunotherapies durvalumab and tremelimumab before standard neoadjuvant chemotherapy and surgery. continue reading »